Up to now, the advanced NSCLC patient with p.E746_S752delinsI still benefited from Icotinib treatment for a total of 19 months, with decreasing tumor burden and CEA level, which showed advanced LADC patients harboring EGFR p.E746_S752delinsI mutation could benefit from Icotinib. The gene discussed is EGFR; the disease is neoplasm.